Previous Article | Next Article 
Molecular and Cellular Biology, September 1998, p. 5567-5578, Vol. 18, No. 9
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Ras-GAP Controls Rho-Mediated Cytoskeletal Reorganization
through Its SH3 Domain
Véronique
Leblanc,*
Bruno
Tocque,
and
Isabelle
Delumeau
Rhône-Poulenc Rorer Central Research,
Gene Medicine Department, Centre de Recherche de Vitry Alfortville,
94403 Vitry sur Seine, France
Received 16 March 1998/Returned for modification 23 April
1998/Accepted 23 June 1998
 |
ABSTRACT |
Proteins of the Ras superfamily, Ras, Rac, Rho, and Cdc42, control
the remodelling of the cortical actin cytoskeleton following growth
factor stimulation. A major regulator of Ras, Ras-GAP, contains several
structural motifs, including an SH3 domain and two SH2 domains, and
there is evidence that they harbor a signalling function. We have
previously described a monoclonal antibody to the SH3 domain of Ras-GAP
which blocks Ras signalling in Xenopus oocytes. We now show
that microinjection of this antibody into Swiss 3T3 cells prevents the
formation of actin stress fibers stimulated by growth factors or
activated Ras, but not membrane ruffling. This inhibition is bypassed
by coinjection of activated Rho, suggesting that the Ras-GAP SH3 domain
is necessary for endogenous Rho activation. In agreement, the antibody
blocks lysophosphatidic acid-induced neurite retraction in
differentiated PC12 cells. Furthermore, we demonstrate that
microinjection of full-length Ras-GAP triggers stress fiber
polymerization in fibroblasts in an SH3-dependent manner, strongly
suggesting an effector function besides its role as a Ras
downregulator. These results support the idea that Ras-GAP connects the
Ras and Rho pathways and, therefore, regulates the actin cytoskeleton
through a mechanism which probably does not involve p190 Rho-GAP.
 |
INTRODUCTION |
Ras is the prototype of a
superfamily of highly conserved proteins. The family can be divided
into several subgroups, Ras, Rho, Rab, ARF (ADP ribosylation factor),
Sar, Ran, and Rad, each of which performs essential cellular functions.
Thus, while Ras proteins have a determinant role in cell growth,
differentiation, and malignant transformation, Rho proteins control the
formation of actin-based cytoskeletal structures, as well as growth
regulation, and Rab proteins participate in intracellular vesicular
transport and secretion (4, 51). In addition, Rho and Rab
proteins have specific roles in cells of the immune system
(8). Ras-like proteins are molecular switches whose activity
is controlled by their bound nucleotide, with the GTP form being the
active form competent for cellular signalling and with the GDP-bound
form being inactive. They are subjected to tight control by regulatory proteins. Activation is brought about by guanine nucleotide exchange factors (GEFs) that favor nucleotide release and GTP loading
following exposure of cells to growth factors. Deactivation is ensured
by GTPase-activating proteins (GAPs) which greatly speed up
GTP hydrolysis. In general, several GEFs and GAPs can regulate the
activity of a single GTPase (3).
Microinjection of activated Ras, Cdc42, Rac, or Rho proteins induces
polymerization of cortical actin, from a preexisting pool of soluble
actin present in resting fibroblasts, into particular structures. It
has been established that Cdc42 causes the formation of filopodia
(23), while Rac generates lamellipodia and membrane ruffles
(44), and that Rho controls stress fiber assembly
(43). Furthermore, the use of dominant negative mutants of
each protein has unraveled complex connections between them. It was
found that activated Cdc42 induces not only filopodia, but also
lamellipodia and ruffles through subsequent activation of endogenous
Rac (23). Likewise, activated Rac can also promote stress
fiber formation, because it can stimulate Rho activity (36,
44). Ras branches in this pathway upstream of Rac and stimulates
ruffling through a Rac-dependent mechanism (44). These
rearrangements are coupled to the clustering of integrins at focal
contacts (36), which are sites of cell attachment to the
extracellular matrix.
Ras-GAP is a major regulator of cellular Ras activity. The
carboxy-terminal half of the protein contains the catalytic domain, which binds Ras-GTP and accelerates GTP hydrolysis (54). In the amino-terminal region lies a Src homology 3 (SH3) domain flanked by
two SH2 domains which mediate interactions with signalling proteins
(i.e., p190 Rho-GAP, Src, and p62), a pleckstrin homology domain, and a
stretch of amino acids involved in calcium-regulated binding to
phospholipids, which mediate interactions with the plasma membrane (see
reference 53 for review). First thought of merely as
a downregulator of Ras (22, 37, 58, 59), its role turned out
to be more complex, and it is now established that Ras-GAP also
mediates some of the biological effects of Ras and, therefore, has some
intrinsic effector function (1, 10, 53). Some data are
consistent with the fact that these effects are relayed via the
NH2-terminus part of Ras-GAP and, more specifically, that
its SH3 domain could be involved. Thus, overexpression of a truncated
mutant Ras-GAP N terminus was found to be a potent suppressor of
Ras-induced transformation (9), whereas overexpression of
the N terminus or of the isolated SH3 domain blocked
carbachol-dependent transformation of NIH 3T3 cells expressing
muscarinic receptors (28, 57). We have previously shown that
microinjection into Xenopus oocytes of a monoclonal antibody
(MAb 200) (32) against human Ras-GAP that specifically
recognizes the SH3 domain was able to inhibit Ras-stimulated, but
not progesterone-stimulated, maturation (11), induction of
c-mos expression, and subsequent activation of p34cdc2
(41).
In other respects, several lines of evidence indicate a connection
between Ras-GAP and the cytoskeleton. It has been reported that Rat-2
cells overexpressing the Ras-GAP N terminus exhibit an abnormal network
of actin fibers and reduced adhesive capacities (30) and
that overexpression of full-length Ras-GAP abolished the
chemotactic response of fibroblasts to platelet-derived growth factor (PDGF) (26). More recently, the abnormal vascular
phenotype displayed by Ras-GAP knockout mouse embryos was
found to be consistent with defective migration of endothelial cells
(18).
A connection between Ras-GAP and the G proteins of the Rho family could
explain the effects of Ras-GAP on cytoskeletal organization mentioned
above. This connection should involve the N-terminus domain of Ras-GAP.
Here we report that injection of the anti-Ras-GAP SH3 antibody MAb 200 into quiescent Swiss 3T3 cells inhibited stress fiber formation in
response to stimulation by several growth factors, but did not block
stress fibers which formed following injection of activated Rho. In
pheochromocytoma PC12 cells, MAb 200 appeared to decrease endogenous
Rho activity and facilitate Ras-induced neurite outgrowth in the
absence of nerve growth factor (NGF); it also blocked neurite
retraction stimulated by lysophosphatidic acid (LPA) in differentiated
cells. These effects were reproduced by a truncated mutant Ras-GAP N
terminus. In addition, we found that Ras-GAP per se had a
signalling function and was able to cause actin polymerization into
stress fibers in Swiss 3T3 cells. Since this activity required the SH3
domain, our results altogether indicate that the SH3 domain of Ras-GAP
is necessary for Rho activation and further establish a molecular basis
for the connection between the Ras and Rho signalling pathways in
mammalian cells. Moreover, we found that the effect of MAb 200 cannot
be explained by a competition with p190 Rho-GAP for binding to Ras-GAP.
 |
MATERIALS AND METHODS |
Cell culture and microinjection.
Rat PC12 pheochromocytoma
cells were cultured in RPMI 1640 medium supplemented with 10% horse
serum and 5% fetal calf serum (FCS). Cells were differentiated for 3 days in a medium containing 1/10 total serum plus 50 ng of NGF per ml.
For microinjection, 2 × 104 cells per ml were seeded
onto squared coverslips (CELLocate) precoated with
poly-L-lysine (10 µg/ml) 2 to 3 days before injection. NGF-differentiated cells were stimulated with 10 µM LPA (Sigma) 2 h after microinjection. Cells were returned to the incubator after injection and regularly checked for morphological changes. Both
the low-density seeding and the squaring allowed the precise identification and follow-up of microinjected cells.
Swiss 3T3 cells were routinely grown in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% FCS. For cytoskeleton studies,
cells were seeded onto CELLocate coverslips and allowed to grow to
confluence in complete medium. To obtain quiescent cells, they were
then starved in DMEM containing 0.2% NaHCO3 and 0.005%
FCS for 48 h. After microinjection, cells were incubated for the
appropriate time at 37°C before growth factor stimulation or
fixation. For the DNA synthesis assay, subconfluent cells were starved
for 24 h in 0.1% FCS and, after injection, incubated for 40 h in the presence of a 1/1,000 bromodeoxyuridine
(BrdU)-fluorodeoxyuridine (FdU) mixture (Amersham) before fixation.
When specified in the text, this medium was supplemented with 100 µM
LPA or 10% FCS. Microinjection was performed with an Eppendorf
transjector 5246 and an Eppendorf micromanipulator 5171. Successful
injection was determined visually at the time of injection and by
immunofluorescence on fixed cells.
Immunofluorescence microscopy.
For actin, phosphotyrosine,
and protein staining, cells were washed in phosphate-buffered saline
for 5 min (or in phosphate-buffered saline plus 1 mM
Na4VO3 for phosphotyrosine staining), fixed in 4% formaldehyde for 15 min, permeabilized in 0.2% Triton X-100 for 5 min, and incubated in Power Block (BioGenex) for 10 min. Actin
filaments were visualized by incubation with 0.5-µg/ml fluorescein isothiocyanate (FITC)-labelled phalloidin (Sigma). Phosphotyrosine residues were detected with a polyclonal antiphosphotyrosine
antibody (Zymed) revealed with an FITC-labelled antirabbit
F(ab')2. Injected glutathione S-transferase
(GST) fusion proteins were detected with a MAb to GST (given by J. Grassi, Centre d'Etudes de Saclay, Gif-sur-Yvette, France), followed
by Texas red-labelled antimouse F(ab')2. MAb 200 or the
control mouse immunoglobulin G (IgG) injected was detected with Texas
red-labelled antimouse F(ab')2; Y13-259-injected cells were
detected with Texas red-labelled antirat F(ab')2. For BrdU
staining, cells were fixed in 90% ethanol-5% acetic acid for 30 min,
permeabilized in 0.1% Tween 20 for 5 min, and subjected to DNase I
digestion (2 µg/ml) in 50 mM Tris (pH 7.5)-10 mM
MgCl2-10 mM MnCl2 for 1 h. They were
stained with a rat antibody to BrdU (Valbiotech), followed by
FITC-coupled antirat F(ab')2. All secondary antibodies were
supplied by Jackson Immunoresearch. In each experiment, cells were
double stained to detect both injected cells and the particular
response under study (cytoskeleton, focal complexes, or DNA synthesis).
Antibodies and recombinant proteins for microinjection.
The
MAb to Ras-GAP SH3, MAb 200, was purified from ascitic fluids (SpiBio,
Massy, France) by caprylic acid precipitation. Rat anti-Ras Y13-259
hybridoma cells were grown in DMEM supplemented with 10% FCS
(Hyclone), 1 mM sodium pyruvate, 2 mM glutamine, and 100 U of
streptomycin per ml. Y13-259 was purified from culture supernatants by
using protein G-Sepharose (Pharmacia). The vector (pGEX-2T) expressing
mutant RhoAV14 cDNA was given by A. Hall. The recombinant GST-RhoA
fusion protein was purified by affinity chromatography on
glutathione-agarose, and GST was removed by thrombin digestion, as
described previously (44). pGEX-3X-p120 GAP was obtained by
inserting human Ras-GAP cDNA digested from a pSV2 vector
(47) into the EcoRI-BamHI sites of
pGEX-3X. GAPSH2-SH3-SH2 (amino acids 182 to 442) was obtained and
cloned into pGEX-2T as described previously (11). GST fusion
proteins were purified by affinity chromatography (11), and
Ha-RasK12 was purified by anion-exchange chromatography
(42).
 |
RESULTS |
Anti-Ras-GAP SH3 antibody inhibits growth factor-induced stress
fiber formation, but not membrane ruffling.
It has previously been
shown that oncogenic Ras promotes cytoskeletal rearrangements in Swiss
3T3 cells. On the other hand, a growing body of evidence shows that
Ras-GAP exerts some effector functions requiring the N-terminal part of
the protein. To assess whether the N terminus of Ras-GAP is required
downstream of Ras in this pathway, we investigated the impact of the
anti-Ras-GAP SH3 antibody MAb 200 on actin stress fiber polymerization
and membrane ruffling stimulated by activated Ras (Ha-RasK12) in
quiescent cells. Two to three hours after injection of Ras plus an
irrelevant IgG, cells exhibited membrane ruffles at their periphery,
which were progressively replaced by a dense stress fiber network (Fig. 1B). After 5 h, only a very few
membrane ruffles were left (Fig. 1C). These structures were absent from
noninjected quiescent cells (Fig. 1A). In cells where MAb 200 was
coinjected with Ras, membrane ruffles developed with the same kinetics
as in control cells (Fig. 1D). In contrast, the presence of the
anti-GAP SH3 antibody almost completely prevented actin polymerization
into stress fibers, and the ruffles persisted for more than 5 h
(Fig. 1E). As a control, the Ras-neutralizing antibody Y13-259
(14) blocked both ruffle and stress fiber formation
stimulated by Ras (not shown).

View larger version (110K):
[in this window]
[in a new window]
|
FIG. 1.
MAb 200, an anti-Ras-GAP SH3 antibody, inhibits
Ras- and PDGF-induced stress fiber formation, but not membrane ruffles,
in Swiss 3T3 cells. Actin structures are shown in
serum-deprived cells, quiescent and uninjected (A) and 3 h (B) or
5 h (C) after coinjection of Ha-RasK12 (1 mg/ml) with a control
mouse IgG (8 mg/ml) and 3 h (D) or 5 h (E) after
coinjection of Ha-RasK12 (1 mg/ml) with MAb 200 (8 mg/ml). (F and G)
Cells were stimulated for 30 min with 3 ng of PDGF per ml
2 h after injection of a control IgG or MAb 200, respectively.
Actin filaments were detected with FITC-conjugated phalloidin. The
white stars indicate noninjected cells.
|
|
Growth factors, such as PDGF, trigger cytoskeletal modifications
similar to those promoted by Ras that are membrane ruffles
and stress
fibers. These PDGF-induced rearrangements are not affected
by the
presence of the neutralizing Y13-259 anti-Ras antibody
(
14),
suggesting that Ras activation was not essential for these
responses
(
44) and that an alternative pathway may exist. To
test
whether MAb 200 could also inhibit stress fiber formation
when it was
stimulated by PDGF, cells were exposed to this growth
factor for 30 min. In contrast with the results obtained with
Y13-259, MAb
200-microinjected cells (Fig.
1G) exhibited membrane
ruffles but had a
lot fewer stress fibers than control cells (Fig.
1F). This result shows
that the involvement of the SH3 domain
of Ras-GAP in this response
overrides the Ras signalling cascade.
Ras- and PDGF-induced membrane
ruffling in Swiss 3T3 cells is
dependent on Rac activation, since it is
blocked by a dominant
inhibitory Rac mutant (
44). Because
activation of Rac in turn
activates Rho, which leads to stress fiber
formation, our results
suggest that MAb 200 inhibits Rho, but not Rac,
activity.
Ras-GAP SH3 domain is involved in Rho activation in response to
growth factors.
To determine if the anti-GAP SH3 antibody can
indeed interfere with Rho signalling, quiescent cells (Fig.
2A) were microinjected with MAb 200 or a
control IgG and then exposed to serum or LPA for 10 or 30 min. LPA
activates Rho, as witnessed by actin polymerization into fibers
(43). This was reproduced in control cells, where a network
of fibers was readily observed after 10 min of LPA stimulation (compare
Fig. 2B and A) or serum (not shown). In contrast, under the same
conditions, no actin cables were seen, or if there were any, they were
few and very thin, in MAb 200-injected cells (Fig. 2C). The number of
stress fibers per cell and their thickness, as carefully estimated
visually, were inversely correlated to the amount of antibody injected
(not shown). After 30 min of serum stimulation, the inhibition of
stress fiber formation produced by MAb 200 was partially relieved,
whereas it was maintained in the case of LPA (data not shown).
Interestingly, injection of MAb 200 per se provoked a complete
disappearance of the few stress fibers that remained in some quiescent
cells (not shown), suggesting that it can also block the low basal
level of Rho activation which is left under these conditions
(19). No inhibition of stress fiber polymerization following
LPA stimulation was observed after injection of the Ras-neutralizing
antibody Y13-259 (Fig. 2D), indicating that Rho induces actin
polymerization independently of Ras.

View larger version (148K):
[in this window]
[in a new window]
|
FIG. 2.
Inhibition of LPA-induced stress fibers by MAb 200 but
not by Y13-259. Actin filaments are shown in serum-starved Swiss 3T3
cells without injection (A) or stimulated with 0.115 µM LPA for 10 min 2 h after injection of a control mouse IgG (B), MAb 200 (C),
or Y13-259 (D). Proteins were injected at a concentration of 8 mg/ml.
Actin filaments were detected with FITC-conjugated phalloidin. All
cells in each field have been injected.
|
|
Focal adhesions are multimolecular complexes containing
tyrosine-phosphorylated proteins, which allow attachment of actin
cables to the cell walls. Their assembly was shown to be regulated
by
Rho (
36). By immunofluorescence with an antiphosphotyrosine
antibody, we studied focal adhesions which formed in response
to serum
or LPA. In quiescent Swiss 3T3 cells, focal complexes
are very few and
sparse (Fig.
3A), which correlates with
the low
abundance of stress fibers. As reported before (
43),
following
addition of LPA or serum, numerous adhesion plaques become
visible
and are evenly distributed at the cell periphery (not shown).
Injection of a fragment of Ras-GAP which contains the isolated
SH2-SH3-SH2 domains (amino acids 182 to 442) fused to GST resulted
in a
large reduction (50 to 80%) in the number of focal adhesions
counted in each cell (Fig.
3D), while GST alone had no inhibitory
effect (Fig.
3B). Moreover, the complexes formed in control cells
seemed morphologically distinct from the few that assembled in
the
presence of GST-GAPSH2-SH3-SH2, the latter being much smaller
and less
elongated. It is possible that these complexes are Rac-
or
Cdc42-regulated complexes (
36). Identical results were
obtained
with MAb 200 (not shown). Staining of cells injected either
with
MAb 200 or with GST-GAPSH2-SH3-SH2 revealed a peculiar
notched-cell
contour that was not observed in control cells
(compare Fig.
3E
and C). This effect could result from disrupted
adhesion of the
cells due to the incomplete response to LPA or serum in
the presence
of the antibody or, alternatively, the formation of
nonfunctional
focal complexes.

View larger version (89K):
[in this window]
[in a new window]
|
FIG. 3.
Inhibition of LPA-induced focal complex assembly by
GST-GAPSH2-SH3-SH2. Focal complexes are shown in serum-deprived Swiss
3T3 cells without injection or stimulation (A) and in cells stimulated
for 10 min with 0.115 µM LPA 2 h after injection of GST (B) or
GST-GAPSH2-SH3-SH2 (D). (C and E) Injected cells corresponding to those
in panels B and D, respectively. Proteins were injected at 1.5 mg/ml.
Cells were double stained with an antiphosphotyrosine antibody,
revealed by an FITC-labelled secondary antibody to detect focal
complexes (left panel), and with an anti-GST antibody, revealed by a
Texas red-labelled secondary antibody to detect injected cells (right
panel). The white star indicates noninjected cells.
|
|
Ras-GAP SH3 domain is implicated in Rho regulation.
Taken
together, these results strongly suggest that the
NH2-terminal region of Ras-GAP, through its SH3 domain,
could behave as a suppressor of the Rho pathway. To determine whether
the activity of Ras-GAP on this pathway is exerted upstream or
downstream from Rho, we tested if MAb 200 could inhibit stress
fibers induced by a constitutively activated Rho mutant. Serum-starved
cells were simultaneously injected with RhoAV14 and MAb 200. Quiescent cells are shown in Fig. 4A. A
few minutes after RhoAV14 injection, actin stress fibers were readily
detectable, and no difference could be observed between control (Fig.
4B) and MAb 200-injected cells (Fig. 4C), even after a 2-h period.
Identical results were obtained when MAb 200 was injected 2 h
before Rho (not shown). The ability of activated Rho to bypass the
inhibition of stress fiber assembly produced by MAb 200 suggests that
the regulatory role of Ras-GAP is exerted upstream from Rho.

View larger version (77K):
[in this window]
[in a new window]
|
FIG. 4.
MAb 200 does not inhibit RhoAV14-induced stress fibers
in Swiss 3T3 cells. The photographs show phalloidin staining of
uninjected cells (A) and cells 2 h after coinjection of RhoAV14
with a control IgG (B) or with MAb 200 (C). RhoAV14 was injected at a
concentration of 0.3 mg/ml, and the antibodies were injected at a
concentration of 8 mg/ml. F-actin was detected with FITC-conjugated
phalloidin. All cells in each field have been injected.
|
|
Full-length Ras-GAP induces the formation of stress fibers.
Having established that overexpression of the NH2-terminal
part of Ras-GAP or inhibition of its SH3 domain downregulates the Rho
pathway, we asked whether full-length Ras-GAP had any effect by itself
on the cytoskeleton. Strikingly, microinjection of full-length Ras-GAP
(fused to GST) in serum-deprived cells induced the appearance of stress
fibers by 4 h (Fig. 5B), whereas
no actin polymerization was observed in control cells injected with GST
(Fig. 5A). Typically, Ras-GAP induced this response in over 60% of the
injected cells. The stress fiber-inducing activity of Ras-GAP requires
functional Rho, as shown by the fact that it was blocked when the C3
exotoxin from Clostridium botulinum, a specific Rho
inhibitor (40), was coinjected with Ras-GAP (compare Fig. 5D
with B and C). We had previously determined the appropriate
concentration of toxin as that necessary to fully inhibit stress fiber
formation stimulated by serum in quiescent cells (not shown). At that
time (4 h after injection), the cells injected with C3 plus GST had a
normal morphology and were viable (Fig. 5C). Interestingly, the effect
of Ras-GAP on the cytoskeleton was independent of Ras because it was
not inhibited (Fig. 5E) by coinjection of the anti-Ras antibody Y13-259 (14). Finally, we showed that the effect of Ras-GAP was
totally abolished when MAb 200 and Ras-GAP (Fig. 5F) or when
GST-GAPSH2-SH3-SH2 and Ras-GAP (not shown) were coinjected; in
contrast, different antibodies directed against the COOH-terminus part
of Ras-GAP had no inhibitory effect (data not shown).

View larger version (154K):
[in this window]
[in a new window]
|
FIG. 5.
Full-length Ras-GAP induces stress fiber polymerization
through its SH3 domain and requires Rho but not Ras activity. Actin
structures are shown in serum-deprived Swiss 3T3 cells 4 h after
microinjection of GST (A), GST-Ras-GAP plus a control mouse IgG (B),
GST plus C3 toxin (C), GST-Ras-GAP plus C3 toxin (D), GST-Ras-GAP plus
Y13-259 (E), and GST-Ras-GAP plus MAb 200 (F). GST and GST-Ras-GAP were
injected at a concentration of 1.5 mg/ml, C3 toxin was injected at 70 µg/ml, and MAb 200, the control IgG, and Y13-259 were injected at 8 mg/ml. F-actin was detected with FITC-conjugated phalloidin. The white
stars indicate noninjected cells.
|
|
Ras-GAP SH3 domain is required for LPA-induced DNA synthesis.
Besides their role in regulating the cytoskeleton, Rho GTPases are
involved in other responses to growth factors, such as promotion of
S-phase entry (38). Given that Rho-mediated cytoskeletal rearrangements are dependent on the Ras-GAP SH3 domain, it was of
interest to determine if this domain was implicated in other events
controlled by Rho. Quiescent cells injected with MAb 200 were tested
for their ability to incorporate BrdU when subjected to serum or LPA
stimulation. LPA induction of DNA synthesis was inhibited by 30 to 50%
by MAb 200 with respect to control IgG-injected cells (Fig.
6), whereas serum was able to induce
DNA replication in 95% of both control and MAb 200-injected cells
(Fig. 6). S-phase entry promoted by activated Ras was also not modified
by MAb 200. Since we previously showed that MAb 200 was able to block
stress fibers but not membrane ruffles induced by Ras, these data
further demonstrate that the Ras-GAP SH3 domain is not required for all Ras-induced events. This finding is in agreement with the idea that
serum stimulates progression into S phase through multiple pathways,
including Ras (33) and Cdc42 (38), the latter of which may not be susceptible to our anti-Ras-GAP antibody. Altogether, our results show that the inhibitory effect of MAb 200 on the Rho
signalling pathway is not restricted to the cytoskeleton but affects
other downstream signals transduced by Rho.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of MAb 200 on DNA synthesis induced by FCS, LPA,
and Ras. For Ras induction of DNA synthesis, MAb 200 (8 mg/ml) or the
control IgG (8 mg/ml) was coinjected with Ha-RasK12 (2 mg/ml) in
serum-deprived cells. After injection, cells were incubated in the
presence of BrdU-FdU for 40 h. For LPA or FCS induction of S-phase
entry, cells were injected with MAb 200 or the control IgG and
incubated in the presence of 100 µM LPA or 10% FCS and BrdU-FdU for
40 h. Cells were then processed for anti-BrdU staining as
described in Materials and Methods. The percentage of MAb 200-injected
cells which incorporated BrdU is compared to that of control
IgG-injected cells, which was taken as 100% for each condition of
stimulation. These control values represent 98% of the injected cells
in the case of FCS stimulation, 80 to 60% in the case of LPA
stimulation, and 50% in the case of Ras injection. The results are the
average ± standard error of three experiments.
|
|
Ras-GAP inhibits Ha-RasK12-induced PC12 differentiation.
The
study of the regulation of the cytoskeleton in rat PC12
pheochromocytoma cells has revealed a crucial role for small G proteins. Indeed, PC12 cells have been shown to differentiate into a
neuron-like phenotype following NGF or Ras stimulation by modifying
their actin cytoskeleton and extending long neurites (2).
Moreover, cell differentiation has also been obtained by specific Rho
inhibition (25, 35). Since our data demonstrate an impact of
Ras-GAP, through its SH3 domain, on cytoskeletal reorganization
controlled by Rho independently of Ras in fibroblasts, we asked whether
Ras-GAP would have a similar function in PC12 cells. In a first
set of experiments, PC12 cells were injected with MAb 200, GST-GAPSH2-SH3-SH2, or GST-Ras-GAP, in the presence or
absence of activated Ras (Ha-RasK12), and observed for several days.
Four days after injection, cells injected with MAb 200 alone (Fig.
7B) or GST-GAPSH2-SH3-SH2 (not shown)
exhibited small neurites that were not seen in control cells injected
with an irrelevant IgG (Fig. 7A). Cells having received MAb 200 and
activated Ras (not shown) or GST-GAPSH2-SH3-SH2 and activated Ras (Fig.
7D) exhibited by 2 days postinjection a fully differentiated phenotype which they retained for more than 6 days. In contrast, at that time,
Ras-plus-GST-injected cells had almost completely lost their differentiated morphology (Fig. 7C). On the other hand, a strong inhibition of Ras-stimulated differentiation was observed at
4 days when GST-Ras-GAP was coinjected with activated
Ras (Fig. 7F), while GST coinjected with Ras had no effect on
differentiation under the same conditions (Fig. 7E). GST-Ras-GAP on its
own did not induce any morphological changes in PC12 cells (not shown). Because Ha-RasK12 cannot be deactivated by Ras-GAP (3), the inhibition of PC12 cell differentiation is unlikely to result from Ras
inactivation, but could rather be the consequence of the activation, by
Ras-GAP, of another pathway which prevents differentiation, such as the
Rho pathway.

View larger version (123K):
[in this window]
[in a new window]
|
FIG. 7.
Effect of MAb 200, GST-GAPSH2-SH3-SH2, and
GST-Ras-GAP on the morphology of PC12 cells. PC12 cells are shown 3 days after injection of a control mouse IgG (A) or MAb 200 (B). Note
the presence of short neurites in MAb 200-injected cells, which are
absent in control cells. In panel C are shown cells 6 days after
coinjection of Ha-RasK12 with GST, while cells injected with Ha-RasK12
and GST-GAPSH2-SH3-SH2 are shown in panel D. Note the difference in
neurite length between panels C and D. Cells coinjected with Ha-RasK12
plus GST are fully differentiated after 4 days (E), whereas those
injected with Ha-RasK12 plus GST-Ras-GAP are not (F). The antibodies
were injected at a concentration of 8 mg/ml, Ha-RasK12 was injected at
1.5 mg/ml, and GST, GST-GAPSH2-SH3-SH2, and GST-Ras-GAP were injected
at 2 mg/ml. The cell clumps in panels E (bottom right corner)
and F (bottom left corner) were not injected; in the other fields, all
cells have been injected or stem from injected cells.
|
|
In a second set of experiments, NGF-differentiated cells were injected
with a control IgG (Fig.
8A) or with MAb
200 (Fig.
8D) and then stimulated with LPA. After 30 min, most neurites
had retracted in control cells, and cells started to detach from
the
tissue culture dish (Fig.
8B). This effect was even more pronounced
after a couple of hours (Fig.
8C). In MAb 200-injected cells,
neurites
had also partially retracted by 30 min (Fig.
8E), but
this phenomenon
was only transient, because they extended back
to their initial
length by 2 h (Fig.
8F). Furthermore, these cells
were no longer
sensitive to the effect of LPA. Given that LPA-stimulated
activation of
Rho induces neurite retraction in NGF-differentiated
cells
(
52), our data suggest that the presence of MAb 200 prevents
Rho from being activated by LPA, possibly by preventing Ras-GAP
from
activating Rho. Altogether, these results show that the Ras-GAP
SH3
domain is not necessary for Ras to differentiate PC12 cells,
but that
Ras-GAP is implicated in the control of differentiation,
probably by
regulating the level of activity of endogenous Rho.

View larger version (88K):
[in this window]
[in a new window]
|
FIG. 8.
MAb 200 protects NGF-differentiated PC12 cells from
LPA-induced neurite retraction and cell rounding. IgG- or MAb
200-injected cells (upper and lower panels, respectively) are shown
2 h postinjection without addition (A and D) or 30 min (B and E)
or 3 h (C and F) after stimulation with 10 µM LPA. All cells in
these fields have been injected.
|
|
 |
DISCUSSION |
This study, initially focused on the role of the Ras-GAP SH3
domain in cytoskeletal changes stimulated by growth factors in quiescent Swiss 3T3 fibroblasts, led us to show that Ras-GAP
microinjection promotes stress fiber assembly independently of any
additional stimulus and, of particular interest, independently of
cellular Ras. In addition, Ras-GAP promotes stress fiber formation in
Swiss 3T3 cells, possibly via activation of Rho, since this effect is blocked by the C3 exotoxin, a specific Rho inhibitor. We propose that
Ras-GAP-induced cytoskeletal reorganization is mediated by its SH3
domain, because the specific anti-GAP SH3 antibody, MAb 200, impedes
this phenomenon. Moreover, this antibody blocked LPA-induced neurite
retraction in differentiated PC12 cells, a response known to be
controlled by Rho. That the inhibition of actin polymerization into
stress cables is bypassed by coinjection of activated Rho further
indicates that MAb 200 suppresses activation of endogenous Rho
stimulated by different growth factors, but has no impact downstream of
Rho. MAb 200 did not cross-react with Rho, ruling out the possibility
that it might act by direct binding to Rho itself (not shown).
Several lines of evidence indicate that the effects of MAb 200 are
highly specific and are not the result of a stress caused by
microinjection of a high concentration of IgG into cells weakened by
serum starvation. First of all, an identical concentration of an
irrelevant antibody had no effect. Second, MAb 200 recognized a single
band of 120 kDa corresponding to Ras-GAP on a blot of extract from
Swiss 3T3 and PC12 cells; in addition, the recombinant Ras-GAP SH3
domain was the only one recognized by the antibody among those tested,
including Src, Fyn, Lck, Grb-2, phospholipase C
, Abl, Nck, and Crk
(data not shown). Moreover, the inhibitory effect of MAb 200 on growth
factor-stimulated stress fiber assembly disappeared when the antibody
was incubated with the Ras-GAP SH3 domain prior to injection; no other
SH3 domain was capable of relieving this effect (not shown). Third, MAb
200 blocked only a defined subset of cellular responses to growth
factors, such as stress fiber and focal adhesion assembly or
LPA-induced DNA synthesis in fibroblasts, as well as LPA-induced
neurite retraction in neuron-like cells, but it did not alter membrane
ruffling, DNA replication stimulated by serum, or differentiation
promoted by oncogenic Ras in PC12 cells. Finally, the effects of the
anti-GAP SH3 antibody were reproduced by a truncation mutant of Ras-GAP consisting of the SH2 and SH3 domains. It is interesting that MAb 200 only partially blocked LPA-stimulated DNA synthesis; this can be
explained by the fact that this response involves additional Rho-independent activities like that of Ras, which is known to be
activated by LPA via a pertussis toxin-dependent mechanism (55), and the mitogen-activated protein kinase cascade
(20).
We have shown for the first time that Ras-GAP can have a proper
effector function independently of Ras, because its
overexpression produces a Rho-like phenotype in resting
fibroblasts, while in association with oncogenic Ras, it considerably
slows down morphological differentiation of PC12 cells. Constructs of
Ras-GAP encompassing the SH2 and SH3 domains have proved to be a
valuable tool for investigating its function, and their use has been
extensively reported in the literature (9, 10, 28, 30, 31).
Similar to our finding that MAb 200 did not inhibit Ras-induced
membrane ruffling, it was recently reported that
GAPSH2-SH3 domain did not alter this response in porcine endothelial
cells (46). GST-GAPSH2-SH3-SH2 as well as MAb 200 were able to slightly differentiate PC12 cells, probably via a
molecular mechanism that does not involve Ras. This was clearly
demonstrated in fibroblasts in which Ras-GAP does not require Ras
activity to induce actin polymerization. Our finding that MAb 200, as
well as GST-GAPSH2-SH3-SH2, greatly potentiated the effect of oncogenic
Ras in prolonging cell differentiation is in accordance with the
finding that PC12 cells overexpressing the Ras-GAP N terminus
differentiated to a greater extent than control cells in response to
NGF and extended longer neurites (34). This effect could be
explained by a concomitant inhibition of the Rho pathway due to Ras-GAP
inactivation, by the anti-Ras-GAP SH3 antibody or by competition with
the inhibitory construct GST-GAPSH2-SH3-SH2, and activation of the Ras
pathway by oncogenic Ras, both able to promote PC12 differentiation.
Our experiments with full-length Ras-GAP in these cells also support
this notion: the inhibition of Ras-induced differentiation probably
results from Rho activation caused by Ras-GAP. Nevertheless, we cannot
exclude the hypothesis of a competition between Ras-GAP and another Ras
effector which is important for differentiation
Raf1, for example
(56).
That Ras-GAP by itself triggers reorganization of the cytoskeleton
independently of Ras was rather unexpected. Previous studies have shown
that microinjection of n-chimaerin, a GAP for Rac1 and
Cdc42, also promotes morphological changes such as filopodia, lamellipodia, and a decrease in the number of stress fibers coupled to
a redistribution of vinculin to the ends of the newly formed actin
structures (24). This effect does not require GAP activity but depends on the ability of n-chimaerin to bind Rac1
and Cdc42, while the isolated GAP domain was ineffective
(24). Our results are somewhat different, in that Ras-GAP
seems to promote cytoskeletal changes in a Ras-independent fashion.
Indeed, stress fiber assembly induced by Ras-GAP was not blocked
by injection of the neutralizing antibody Y13-259, which has been shown
to prevent Ras-GAP from binding to Ras (42). This is also
consistent with the very low level of active GTP-bound Ras which must
be left in Swiss 3T3 cells after serum deprivation. Moreover, Y13-259
does not block stress fiber formation in response to LPA, whereas
the anti-GAP SH3 antibody MAb 200 does, which indicates that Ras-GAP is
not solely an effector of Ras, but can exert additional functions independently. The ability of Ras-GAP to rearrange the actin
cytoskeleton depends on the SH3 domain, because it was inhibited by MAb
200 but not by antibodies directed against the carboxy-terminal part of
the protein, ruling out the possibility that the inhibitory effect of
MAb 200 is due to the sequestering of Ras-GAP to an abnormal cellular
location or to Ras-GAP degradation. Finally, Ras-GAP-induced actin
polymerization into stress fibers results from the subsequent
activation of Rho, since it was inhibited by the C3 toxin.
Our results demonstrate that the Ras-GAP SH3 domain is required for Rho
activation. Theoretically, Rho activation can be achieved via either
stimulation of Rho guanine nucleotide exchange factors (GEFs),
inhibition of Rho-GAP activity, or a combination of both. Two
interpretations, consistent with our findings, can be put forward. In
the first scenario, stimulation of quiescent cells with serum or LPA
would lead to the association of Ras-GAP with a protein required for
Rho activation, such as a Rho-GEF, that would only be active when bound
to Ras-GAP. MAb 200 would displace from Ras-GAP, and thereby
inactivate, the Rho activator. For its part, the truncated version of
Ras-GAP, Ras-GAPSH2-SH3-SH2, would compete with endogenous Ras-GAP for
binding to the Rho activator, but would be unable to stimulate it and,
therefore, would block stress fiber assembly.
A second hypothesis, in which stimulation of quiescent cells with serum
or LPA would lead to the association of Ras-GAP with a Rho inhibitor,
such as Rho-GDI (13, 16) or p190 Rho-GAP (5, 12, 45,
48, 49), is also possible. This association would suppress the
function of the inhibitor, thereby allowing GTP loading on Rho to take
place. It is currently not known if, besides p190 and p190 B
(6), other Rho-GAPs can associate with Ras-GAP, but it is
worth noting that several of them contain a proline-rich sequence
(27). In this case, MAb 200 would release the inhibitor from
Ras-GAP and prevent Rho from being activated, while Ras-GAPSH2-SH3-SH2
would compete with Ras-GAP for binding to the inhibitor but would form
unstable complexes that release the inhibitor. However, our results
strongly suggest that this inhibitor is unlikely to be p190 Rho-GAP,
because MAb 200 did not displace p190 from Ras-GAP, nor did it increase
their association. Western blots probed with an anti-p190 antibody, or
with an anti-Ras-GAP antibody, revealed that p190 came down with
Ras-GAP when it was precipitated with the anti-SH3 domain antibody MAb
200 or with an antibody against the COOH-terminal domain, 15F8
(39) (data not shown). This result is not surprising, since
it has been established that tyrosine-phosphorylated p190 binds the SH2
domains of Ras-GAP (5, 21). It remains possible, however,
that the effect of MAb 200 or Ras-GAPSH2-SH3-SH2 on p190 might be more
subtle, such as, for instance, modulation of the Rho-GAP activity of
p190 when bound to Ras-GAP.
In any case, the assumption that the Rho regulatory protein, be it
activator or inhibitor, binds directly to the Ras-GAP SH3 domain
implies that it contains either a consensus proline-rich sequence
(29) or, alternatively, a WW domain (50). As far as we know, none of the Rho-GEFs or Rho GDP dissociation inhibitors (GDIs) described to date have been reported to have such motifs. It may
indicate that the interaction with Ras-GAP is indirect and requires an
intermediate partner. Nevertheless, it does not preclude the existence
of a new Rho-GEF or Rho-GDI not yet identified and able to bind SH3
domains, given that there are already known GEFs for Ras and Rap1,
i.e., Sos (7) and C3G (17), respectively, which
bind the SH3 domains of the Grb2 and Crk adapter proteins respectively.
Interestingly, Gebbink et al. have described a new protein, p116 Rip,
that could fit with this hypothesis (15). p116 Rip is a
Rho-interacting protein whose overexpression in neuroblastoma N1E-115
cells causes cell flattening and neurite outgrowth in the presence of
serum which contains LPA. This protein is thus a suppressor of Rho.
Importantly, this protein is a putative SH3 binding protein with
proline-rich sequences which are necessary for induction of
morphological differentiation (15).
Overall, the results presented here provide a clue to how Rho gets
activated by growth factors and shed new light on a putative effector
function for Ras-GAP in regulating cytoskeletal organization.
 |
ACKNOWLEDGMENTS |
We are grateful to A. Hall for the Rho expression plasmid
and J. Grassi for providing antibodies. We thank J. Vassy
and D. Schoevaert (Laboratoire d'Analyse d'Image et Pathologie
Cellulaire, Hôpital Saint Louis, Paris, France) for confocal
analysis of the cytoskeleton in some experiments. Thanks go to F. Risbec and S. Bouvier for plasmids and recombinant proteins and M. Kenigsberg and F. Parker for helpful advice. We also acknowledge A. Ridley for critical reading of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: ExonHit
Therapeutics, 65 Bld Massena, 75013 Paris, France. Phone: 331 53 94 77 00. Fax: 331 53 94 77 07. E-mail:
veronique.leblanc{at}exonhit.com.
Present address: ExonHit Therapeutics, 75013 Paris, France.
 |
REFERENCES |
| 1.
|
Abdellatif, M., and M. D. Schneider.
1997.
An effector-like function of Ras GTPase-activating protein predominates in cardiac muscle cells.
J. Biol. Chem.
272:525-533[Abstract/Free Full Text].
|
| 2.
|
Bar-Sagi, D., and J. R. Feramisco.
1985.
Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation.
Cell
42:841-848[Medline].
|
| 3.
|
Boguski, M. S., and F. McCormick.
1993.
Proteins regulating Ras and its relative.
Nature
366:643-654[Medline].
|
| 4.
|
Bokoch, G. M., and C. J. Der.
1993.
Emerging concepts in the Ras superfamily of GTP-binding proteins.
FASEB J.
7:750-759[Abstract].
|
| 5.
|
Bryant, S. S.,
S. Briggs,
T. E. Smithgall,
G. A. Martin,
F. McCormick,
J. H. Chang,
S. J. Parsons, and R. Jove.
1995.
Two SH2 domains of p120 Ras GTPase-activating protein bind synergistically to tyrosine phosphorylated p190 Rho GTPase-activating protein.
J. Biol. Chem.
270:17947-17952[Abstract/Free Full Text].
|
| 6.
|
Burbelo, P. D.,
S. Miyamoto,
A. Utani,
S. Brill,
K. M. Yamada,
A. Hall, and Y. Yamada.
1995.
p190-B, a new member of the Rho GAP family, and Rho are induced to cluster after integrin cross-linking.
J. Biol. Chem.
270:30919-30926[Abstract/Free Full Text].
|
| 7.
|
Chardin, P.,
J. H. Camonis,
N. W. Gale,
L. Van Aelst,
J. Schlessinger,
M. H. Wigler, and D. Bar-Sagi.
1993.
Human Sos1: a guanine nucleotide exchange factor for Ras that binds to Grb2.
Science
260:1338-1343[Abstract/Free Full Text].
|
| 8.
|
Chavrier, P.,
J. P. Gorvel, and J. Bertoglio.
1993.
An immunologist's look at the Rho and Rab GTP-binding proteins.
Immunol. Today
14:440-444[Medline].
|
| 9.
|
Clark, G. J.,
L. A. Quilliam,
M. M. Hisaka, and C. J. Der.
1993.
Differential antagonism of Ras biological activity by catalytic Src homology domains of Ras GTPase activating protein.
Proc. Natl. Acad. Sci. USA
90:4887-4891[Abstract/Free Full Text].
|
| 10.
|
Clark, G. J.,
J. K. Westwick, and C. J. Der.
1997.
p120 GAP modulates Ras activation of jun kinases and transformation.
J. Biol. Chem.
272:1677-1681[Abstract/Free Full Text].
|
| 11.
|
Duchesne, M.,
F. Schweighoffer,
F. Parker,
F. Clerc,
Y. Frobert,
M. N. Thang, and B. Tocqué.
1993.
Identification of the SH3 domain of GAP as an essential sequence for Ras-GAP-mediated signaling.
Science
259:525-528[Abstract/Free Full Text].
|
| 12.
|
Ellis, C.,
M. Moran,
F. McCormick, and T. Pawson.
1990.
Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases.
Nature
343:377-381[Medline].
|
| 13.
|
Fukumoto, Y.,
K. Kaibuchi,
Y. Hori,
H. Fujioka,
S. Araki,
T. Ueda,
A. Kikuchi, and Y. Takai.
1990.
Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the rho proteins, ras p21-like small GTP-binding proteins.
Oncogene
5:1321-1328[Medline].
|
| 14.
|
Furth, M. E.,
L. J. Davis,
B. Fleurdelys, and E. M. Scolnick.
1982.
Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family.
J. Virol.
43:294-304[Abstract/Free Full Text].
|
| 15.
|
Gebbink, M. F. B. G.,
O. Kranenburg,
M. Poland,
F. P. G. van Horck,
B. Houssa, and W. H. Moolenaar.
1997.
Identification of a novel, putative Rho-specific GDP/GTP exchange factor and a RhoA-binding protein: control of neuronal morphology.
J. Cell Biol.
137:1603-1613[Abstract/Free Full Text].
|
| 16.
|
Gosser, Y. Q.,
T. K. Nomanbhoy,
B. Aghazadeh,
D. Manor,
C. Combs,
R. A. Cerione, and M. K. Rosen.
1997.
C-terminal binding domain of Rho GDP-dissociation inhibitor directs N-terminal inhibitory peptide to GTPases.
Nature
387:814-819[Medline].
|
| 17.
|
Gotoh, T.,
S. Hattori,
S. Nakamura,
H. Kitayama,
M. Noda,
Y. Takai,
K. Kaibuchi,
H. Matsui,
O. Hatase,
H. Takahashi,
T. Kurata, and M. Matsuda.
1995.
Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G.
Mol. Cell. Biol.
15:6746-6753[Abstract].
|
| 18.
|
Henkemeyer, M.,
D. J. Rossi,
D. P. Holmyard,
M. C. Puri,
G. Mbamalu,
K. Harpal,
T. S. Shih,
T. Jacks, and T. Pawson.
1995.
Vascular system defects and neuronal apoptosis in mice lacking Ras-GTPase-activating protein.
Nature
377:695-701[Medline].
|
| 19.
|
Hotchin, N. A., and A. Hall.
1995.
The assembly of integrin adhesion complexes requires both extracellular matrix and intracellular rho/rac GTPases.
J. Cell. Biol.
131:1857-1865[Abstract/Free Full Text].
|
| 20.
|
Howe, L. R., and C. J. Marshall.
1993.
Lysophosphatidic acid stimulates mitogen-activated protein kinase activation via a G-protein-coupled pathway requiring p21ras and p74raf-1.
J. Biol. Chem.
268:20717-20720[Abstract/Free Full Text].
|
| 21.
|
Hu, K. Q., and J. Settleman.
1997.
Tandem SH2 binding sites mediate the RasGAP-RhoGAP interaction: a conformational mechanism for SH3 domain regulation.
EMBO J.
16:473-483[Medline].
|
| 22.
|
Huang, D. C. S.,
C. J. Marshall, and J. F. Hancock.
1993.
Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function.
Mol. Cell. Biol.
13:2420-2431[Abstract/Free Full Text].
|
| 23.
|
Kozma, R.,
S. Ahmed,
A. Best, and L. Lim.
1995.
The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts.
Mol. Cell. Biol.
15:1942-1952[Abstract].
|
| 24.
|
Kozma, R.,
S. Ahmed,
A. Best, and L. Lim.
1996.
The GTPase-activating protein n-chimaerin cooperates with Rac1 and Cdc42Hs to induce the formation of lamellipodia and filopodia.
Mol. Cell. Biol.
16:5069-5080[Abstract].
|
| 25.
|
Kozma, R.,
S. Sarner,
S. Ahmed, and L. Lim.
1997.
Rho family GTPases and neuronal growth cone remodelling: relationship between increased complexity induced by Cdc42Hs, Rac1, and acetylcholine and collapse induced by RhoA and lysophosphatidic acid.
Mol. Cell. Biol.
17:1201-1211[Abstract].
|
| 26.
|
Kundra, V.,
B. Anand-Apte,
L. A. Feig, and B. R. Zetter.
1995.
The chemotactic response to PDGF-BB: evidence of a role for Ras.
J. Cell Biol.
130:725-731[Abstract/Free Full Text].
|
| 27.
|
Lamarche, N., and A. Hall.
1994.
GAPs for rho-related GTPases.
Trends Genet.
10:436-440[Medline].
|
| 28.
|
Mattingly, R. R.,
A. Sorisky,
M. R. Brann, and I. G. Macara.
1994.
Muscarinic receptors transform NIH 3T3 cells through a Ras-dependent signalling pathway inhibited by the Ras-GTPase-activating protein SH3 domain.
Mol. Cell. Biol.
14:7943-7952[Abstract/Free Full Text].
|
| 29.
|
Mayer, B. J., and M. J. Eck.
1995.
Minding your p's and q's.
Curr. Biol.
5:364-367[Medline].
|
| 30.
|
McGlade, J.,
B. Brunkhors,
D. Anderson,
G. Mbamalu,
J. Settleman,
S. Dedhar,
M. Rozakis-Adcock,
L. B. Chen, and T. Pawson.
1993.
The N-terminal region of GAP regulates cytoskeletal structure and cell adhesion.
EMBO J.
12:3073-3081[Medline].
|
| 31.
|
Medema, R. H.,
W. L. de Laat,
G. A. Martin,
F. McCormick, and J. L. Bos.
1992.
GTPase-activating protein SH2-SH3 domains induce gene expression in a Ras-dependent fashion.
Mol. Cell. Biol.
12:3425-3430[Abstract/Free Full Text].
|
| 32.
|
Mollat, P.,
G. Y. Zhang,
Y. Frobert,
Y. H. Zhang,
A. Fournier,
J. Grassi, and M. N. Thang.
1992.
Non-neutralizing monoclonal antibodies against Ras GTPase-activating protein: production, characterization and use in an enzyme immunometric assay.
Bio/Technology
10:1151-1155[Medline].
|
| 33.
|
Mulcahy, L. S.,
M. R. Smith, and D. W. Stacey.
1985.
Requirement for ras proto-oncogene function during serum-stimulated growth of NIH3T3 cells.
Nature
313:241-243[Medline].
|
| 34.
|
Nakata, H., and Y. Watanabe.
1996.
Proliferation and differentiation of PC12 cells were affected by p21ras GTPase activating proteins and its deletion mutant proteins.
Biochem. Biophys. Res. Commun.
218:538-543[Medline].
|
| 35.
|
Nishiki, T.,
S. Narumiya,
N. Morii,
M. Yamamoto,
M. Fujiwara,
Y. Kamata,
G. Sakaguchi, and S. Kozaki.
1990.
ADP-ribosylation of the rho/rac proteins induces growth inhibition, neurite outgrowth and acetylcholine esterase in cultured PC12 cells.
Biochem. Biophys. Res. Commun.
167:265-272[Medline].
|
| 36.
|
Nobes, C. D., and A. Hall.
1995.
Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lammelipodia, and filopodia.
Cell
81:53-62[Medline].
|
| 37.
|
Nori, M.,
U. S. Vogel,
J. B. Gibbs, and M. J. Weber.
1991.
Inhibition of v-src-induced transformation by a GTPase-activating protein.
Mol. Cell. Biol.
11:2812-2818[Abstract/Free Full Text].
|
| 38.
|
Olson, M. F.,
A. Ashworth, and A. Hall.
1995.
An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1.
Science
269:1270-1272[Abstract/Free Full Text].
|
| 39.
|
Parker, F.,
F. Maurier,
I. Delumeau,
M. Duchesne,
D. Faucher,
L. Debussche,
A. Dugue,
F. Schweighoffer, and B. Tocque.
1996.
A Ras-GTPase-activating protein SH3 domain-binding protein.
Mol. Cell. Biol.
16:2561-2569[Abstract].
|
| 40.
|
Paterson, H.,
A. J. Self,
M. D. Garrett,
I. Just,
K. Aktories, and A. Hall.
1990.
Microinjection of recombinant p21rho induces rapid changes in cell morphology.
J. Cell Biol.
111:1001-1007[Abstract/Free Full Text].
|
| 41.
|
Pomerance, M.,
M. N. Thang,
B. Tocque, and M. Pierre.
1996.
The Ras-GTPase-activating protein SH3 domain is required for Cdc2 activation and Mos induction by oncogenic Ras in Xenopus oocytes independently of mitogen-activated protein kinase activation.
Mol. Cell. Biol.
16:3179-3186[Abstract].
|
| 42.
|
Rey, I.,
P. Soubigou,
L. Debussche,
C. David,
A. Morgat,
P. E. Bost,
J. F. Mayaux, and B. Tocque.
1989.
Antibodies to synthetic peptide from the residue 33 to 42 domain of c-Ha-ras p21 block reconstitution of the protein with different effectors.
Mol. Cell. Biol.
9:3904-3910[Abstract/Free Full Text].
|
| 43.
|
Ridley, A. J., and A. Hall.
1992.
The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors.
Cell
70:389-399[Medline].
|
| 44.
|
Ridley, A. J.,
H. F. Paterson,
C. L. Johnston,
D. Diekmann, and A. Hall.
1992.
The small GTP-binding protein rac regulates growth factor-induced membrane ruffling.
Cell
70:401-410[Medline].
|
| 45.
|
Ridley, A. J.,
A. J. Self,
F. Kasmi,
H. F. Paterson,
A. Hall,
C. J. Marshall, and C. Ellis.
1993.
Rho family GTPase activating proteins p190, bcr and rho-GAP show distinct specificities in vitro and in vivo.
EMBO J.
12:5151-5160[Medline].
|
| 46.
|
Rodriguez-Viciana, P.,
P. H. Warne,
A. Khwaja,
B. M. Marte,
D. Pappin,
P. Das,
M. D. Waterfield,
A. J. Ridley, and J. Downward.
1997.
Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by ras.
Cell
89:457-467[Medline].
|
| 47.
|
Schweighoffer, F.,
I. Barlat,
M. C. Chevallier-Multon, and B. Tocqué.
1992.
Implication of GAP in Ras-dependent transactivation of a polyoma enhancer sequence.
Science
256:825-827[Abstract/Free Full Text].
|
| 48.
|
Settleman, J.,
V. Narasimhan,
L. C. Foster, and R. A. Weinberg.
1992.
Molecular cloning of cDNAs encoding the GAP-associated protein p190: implications for a signaling pathway from Ras to the nucleus.
Cell
69:539-549[Medline].
|
| 49.
|
Settleman, J.,
C. F. Albright,
L. C. Foster, and R. A. Weinberg.
1992.
Association between GTPase activators for Rho and Ras families.
Nature
359:153-154[Medline].
|
| 50.
|
Sudol, M.
1996.
The WW module competes with the SH3 domain?
Trends Biochem. Sci.
21:161-163[Medline].
|
| 51.
|
Tapon, N., and A. Hall.
1997.
Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton.
Curr. Opin. Cell Biol.
9:86-92[Medline].
|
| 52.
|
Tigyi, G.,
D. J. Fischer,
A. Sebök,
C. Yang,
D. L. Dyer, and R. Miledi.
1996.
Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca2+ signaling and rho.
J. Neurochem.
66:537-548[Medline].
|
| 53.
|
Tocqué, B.,
I. Delumeau,
F. Parker,
F. Maurier,
M. C. Multon, and F. Schweighoffer.
1997.
Ras-GTPase activating protein (GAP): a putative effector for Ras.
Cell. Signalling
9:153-158[Medline].
|
| 54.
|
Trahey, M., and F. McCormick.
1987.
A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants.
Science
238:542-545[Abstract/Free Full Text].
|
| 55.
|
vanCorven, E. J.,
P. L. Hordijk,
R. H. Medema,
J. L. Bos, and W. H. Moolenaar.
1993.
Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts.
Proc. Natl. Acad. Sci. USA
90:1257-1261[Abstract/Free Full Text].
|
| 56.
|
Wood, K. W.,
H. Qi,
G. D'Arcangelo,
R. C. Armstrong,
T. M. Roberts, and S. Halegoua.
1993.
The cytoplasmic raf oncogene induces a neuronal phenotype in PC12 cells: a potential role for cellular raf kinases in neuronal growth factor signal transduction.
Proc. Natl. Acad. Sci. USA
90:5016-5020[Abstract/Free Full Text].
|
| 57.
|
Xu, N.,
F. McCormick, and J. S. Gutkind.
1994.
The non-catalytic domain of ras-GAP inhibits transformation induced by G protein coupled receptors.
Oncogene
9:597-601[Medline].
|
| 58.
|
Yao, R., and G. M. Cooper.
1995.
Regulation of the Ras signaling pathway by GTPase-activating protein in PC12 cells.
Oncogene
11:1607-1614[Medline].
|
| 59.
|
Zhang, K.,
J. E. DeClue,
W. C. Vass,
A. G. Papageorge,
F. McCormick, and D. R. Lowy.
1990.
Suppression of c-ras transformation by GTPase-activating protein.
Nature
346:754-756[Medline].
|
Molecular and Cellular Biology, September 1998, p. 5567-5578, Vol. 18, No. 9
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pham, C. D., Yu, Z., Sandrock, B., Bolker, M., Gold, S. E., Perlin, M. H.
(2009). Ustilago maydis Rho1 and 14-3-3 Homologues Participate in Pathways Controlling Cell Separation and Cell Polarity. Eukaryot Cell
8: 977-989
[Abstract]
[Full Text]
-
Lad, Y., McHugh, B., Hodkinson, P. S., MacKinnon, A. C., Haslett, C., Ginsberg, M. H., Sethi, T.
(2006). Phospholipase C{epsilon} Suppresses Integrin Activation. J. Biol. Chem.
281: 29501-29512
[Abstract]
[Full Text]
-
Yang, J.-Y., Walicki, J., Michod, D., Dubuis, G., Widmann, C.
(2005). Impaired Akt Activity Down-Modulation, Caspase-3 Activation, and Apoptosis in Cells Expressing a Caspase-resistant Mutant of RasGAP at Position 157. Mol. Biol. Cell
16: 3511-3520
[Abstract]
[Full Text]
-
Bartling, B., Yang, J.-Y., Michod, D., Widmann, C., Lewensohn, R., Zhivotovsky, B.
(2004). RasGTPase-activating protein is a target of caspases in spontaneous apoptosis of lung carcinoma cells and in response to etoposide. Carcinogenesis
25: 909-921
[Abstract]
[Full Text]
-
Yue, Y., Lypowy, J., Hedhli, N., Abdellatif, M.
(2004). Ras GTPase-activating Protein Binds to Akt and Is Required for Its Activation. J. Biol. Chem.
279: 12883-12889
[Abstract]
[Full Text]
-
Murai, K. K., Pasquale, E. B.
(2003). `Eph'ective signaling: forward, reverse and crosstalk. J. Cell Sci.
116: 2823-2832
[Abstract]
[Full Text]
-
Chen, J. C., Zhuang, S., Nguyen, T. H., Boss, G. R., Pilz, R. B.
(2003). Oncogenic Ras Leads to Rho Activation by Activating the Mitogen-activated Protein Kinase Pathway and Decreasing Rho-GTPase-activating Protein Activity. J. Biol. Chem.
278: 2807-2818
[Abstract]
[Full Text]
-
McFarlin, D. R., Lindstrom, M. J., Gould, M. N.
(2003). Affinity with Raf is sufficient for Ras to efficiently induce rat mammary carcinomas. Carcinogenesis
24: 99-105
[Abstract]
[Full Text]
-
Gigoux, V., L'Hoste, S., Raynaud, F., Camonis, J., Garbay, C.
(2002). Identification of Aurora Kinases as RasGAP Src Homology 3 Domain-binding Proteins. J. Biol. Chem.
277: 23742-23746
[Abstract]
[Full Text]
-
Gingras, M.-C., Champagne, C., Roy, M., Lavoie, J. N.
(2002). Cytoplasmic Death Signal Triggered by Src-Mediated Phosphorylation of the Adenovirus E4orf4 Protein. Mol. Cell. Biol.
22: 41-56
[Abstract]
[Full Text]
-
Yang, J.-Y., Widmann, C.
(2001). Antiapoptotic Signaling Generated by Caspase-Induced Cleavage of RasGAP. Mol. Cell. Biol.
21: 5346-5358
[Abstract]
[Full Text]
-
Hosooka, T., Noguchi, T., Nagai, H., Horikawa, T., Matozaki, T., Ichihashi, M., Kasuga, M.
(2001). Inhibition of the Motility and Growth of B16F10 Mouse Melanoma Cells by Dominant Negative Mutants of Dok-1. Mol. Cell. Biol.
21: 5437-5446
[Abstract]
[Full Text]
-
Kulkarni, S. V., Gish, G., van der Geer, P., Henkemeyer, M., Pawson, T.
(2000). Role of P120 Ras-Gap in Directed Cell Movement. JCB
149: 457-470
[Abstract]
[Full Text]
-
Masuelli, L., Ettenberg, S., Vasaturo, F., Vestergaard-Sykes, K., Cutler, M. L.
(1999). The Ras Suppressor, RSU-1, Enhances Nerve Growth Factor-induced Differentiation of PC12 Cells and Induces p21CIP Expression. Cell Growth Differ.
10: 555-564
[Abstract]
[Full Text]
-
Wu, G. Y., Zou, D. J., Rajan, I., Cline, H.
(1999). Dendritic Dynamics In Vivo Change during Neuronal Maturation. J. Neurosci.
19: 4472-4483
[Abstract]
[Full Text]
-
Tang, Y., Yu, J., Field, J.
(1999). Signals from the Ras, Rac, and Rho GTPases Converge on the Pak Protein Kinase in Rat-1 Fibroblasts. Mol. Cell. Biol.
19: 1881-1891
[Abstract]
[Full Text]
-
Drugan, J. K., Rogers-Graham, K., Gilmer, T., Campbell, S., Clark, G. J.
(2000). The Ras/p120 GTPase-activating Protein (GAP) Interaction Is Regulated by the p120 GAP Pleckstrin Homology Domain. J. Biol. Chem.
275: 35021-35027
[Abstract]
[Full Text]